Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
1.000
-0.080 (-7.44%)
Mar 13, 2025, 4:00 PM EST - Market closed
Inozyme Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 20.8 | 20.8 | 20.83 | 19.63 | 11.25 | |
| Research & Development | 83.23 | 54.85 | 47.85 | 37.02 | 45.79 | |
| Operating Expenses | 104.03 | 75.65 | 68.68 | 56.65 | 57.04 | |
| Operating Income | -104.03 | -75.65 | -68.68 | -56.65 | -57.04 | |
| Interest Expense | -5.56 | -3.33 | -0.26 | - | - | |
| Interest & Investment Income | 7.67 | 7.84 | 2.2 | 0.21 | 0.37 | |
| Currency Exchange Gain (Loss) | - | - | - | -0.03 | 0.25 | |
| Other Non Operating Income (Expenses) | -0.1 | -0.03 | -0.32 | -0.16 | - | |
| Pretax Income | -102.02 | -71.17 | -67.06 | -56.62 | -56.42 | |
| Net Income | -102.02 | -71.17 | -67.06 | -56.62 | -56.42 | |
| Net Income to Common | -102.02 | -71.17 | -67.06 | -56.62 | -56.42 | |
| Shares Outstanding (Basic) | 63 | 52 | 38 | 24 | 11 | |
| Shares Outstanding (Diluted) | 63 | 52 | 38 | 24 | 11 | |
| Shares Change (YoY) | 21.17% | 37.27% | 60.30% | 113.46% | 832.81% | |
| EPS (Basic) | -1.62 | -1.37 | -1.78 | -2.40 | -5.11 | |
| EPS (Diluted) | -1.62 | -1.37 | -1.78 | -2.40 | -5.11 | |
| Free Cash Flow | -91.97 | -70.97 | -58.17 | -48.55 | -36.54 | |
| Free Cash Flow Per Share | -1.46 | -1.37 | -1.54 | -2.06 | -3.31 | |
| EBITDA | -103.29 | -74.81 | -67.93 | -55.97 | -56.82 | |
| D&A For EBITDA | 0.74 | 0.83 | 0.74 | 0.67 | 0.22 | |
| EBIT | -104.03 | -75.65 | -68.68 | -56.65 | -57.04 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.